Halozyme Therapeutics, Inc. (HALO) earnings
HALO earnings moved a median of +0.40% by the close. Quarterly and annual HALO reports and results, each read against the price at its own news timestamp. Back to the HALO overview →
30 measured HALO earnings events.
Where these HALO earnings landedvs 30 measured HALO earnings reactions
| Middle 50% of HALO earnings reactions | +0.07% to +2.69% |
|---|---|
| Median reaction (to close) | +0.40% |
| Measured reactions | 30 |
Point-in-time · zero look-ahead
Half of the 30 HALO earnings events with a measured close landed between +0.07% and +2.69%; 77% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q HALOZYME THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | +2.33% | +13.32% | |
| HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE | Press release | +2.33% | +13.32% | |
| Halozyme to Report Second Quarter 2026 Financial and Operating Results | Press release | +0.59% | +4.40% | |
| Form 10-Q HALOZYME THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | -1.57% | +0.20% | |
| HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE | Press release | -1.57% | +0.20% | |
| Halozyme to Report First Quarter 2026 Financial and Operating Results | Press release | -0.72% | +0.76% | |
| Form 10-K HALOZYME THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -2.44% | -6.15% | |
| Form 10-Q HALOZYME THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | -3.13% | +0.07% | |
| HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS | Press release | -3.13% | +0.07% | |
| Halozyme to Report Third Quarter 2025 Financial and Operating Results | Press release | +0.57% | +0.53% | |
| Form 10-Q HALOZYME THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | -1.45% | -1.81% | |
| HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS | Press release | -1.45% | -1.81% | |
| Halozyme to Report Second Quarter 2025 Financial and Operating Results | Press release | +1.04% | +2.66% | |
| Form 10-Q HALOZYME THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | +0.03% | +10.13% | |
| HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS | Press release | +0.03% | +10.13% | |
| Halozyme to Report First Quarter 2025 Financial and Operating Results | Press release | +1.75% | +0.27% | |
| Form 10-K HALOZYME THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -3.03% | -2.08% | |
| Form 10-Q HALOZYME THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | -3.40% | +2.69% | |
| HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS | Press release | -3.40% | +2.69% | |
| Halozyme to Report Third Quarter 2024 Financial and Operating Results | Press release | -2.26% | -2.93% | |
| Form 10-Q HALOZYME THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | -3.71% | -3.36% | |
| HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS | Press release | -3.71% | -3.36% | |
| Halozyme to Report Second Quarter 2024 Financial and Operating Results | Press release | +0.58% | +2.10% | |
| Form 10-Q HALOZYME THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | +1.61% | +0.14% | |
| HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS | Press release | +1.61% | +0.14% | |
| Halozyme to Report First Quarter 2024 Financial and Operating Results | Press release | +0.17% | +0.57% | |
| Form 10-K HALOZYME THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -0.15% | +1.70% | |
| Form 10-Q HALOZYME THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | +0.76% | +5.84% | |
| HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS | Press release | +0.76% | +5.84% | |
| Halozyme To Report Third Quarter 2023 Financial and Operating Results | Press release | +0.24% | +0.18% |
Keep exploring
More HALO: analyst actions → · SEC filings → · HALO overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Autolus Therapeutics plc - American Depositary Shares (AUTL) | 377 | -0.00% | 45% |
| Solid Biosciences Inc. (SLDB) | 375 | -0.17% | 46% |
| RITTER PHARMACEUTICALS (RTTR) | 374 | -0.61% | 37% |
| MIRAGEN THERAPEUTICS INC (MGEN) | 369 | -0.39% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.